News | June 23, 2025
Emcure to acquire remaining stake in Zuventus Healthcare
The transaction is expected to close in Q2 FY 2026
The transaction is expected to close in Q2 FY 2026
The proceeds from the QIP will be utiized for purchase of outstanding optionally convertible debentures
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
The approval is for the generic version of Victoza, indicated for the treatment of insufficiently controlled Type 2 Diabetes Mellitus
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
Orion will be the exclusive partner for the distribution, marketing, and sales of Shilpa's Recombinant Human Albumin in Europe
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
CRL shall invest another Rs. 200 crore for creation of additional beds
Shilpa Pharma Lifesciences, Unit-1, received EIR from USFDA
The CDMO upgrade represents a transformational step for Remedium Lifecare
Subscribe To Our Newsletter & Stay Updated
